Protocol No
BI-1403-0019-BRIGHTLINE-4
Phase
III
Summary
This study is being done to test the safety and effectiveness of the study drug, Brigimadlin, in subjects with DDLPS.
Brigimadlin has not been approved by the U.S. Food and Drug Administration (FDA) as a treatment for any disease and is experimental for this study.
Description
Study to test how well brigimadlin is tolerated by people with a type of cancer called dedifferentiated liposarcoma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
ClinicalTrials.gov